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Background. The aims of this study were to identify common patterns of comorbidities observed in people living with HIV 
(PLWH), using a data-driven approach, and evaluate associations between patterns identified.
Methods. A wide range of comorbidities were assessed in PLWH participating in 2 independent cohorts (POPPY: UK/Ireland; 
AGEhIV: Netherlands). The presence/absence of each comorbidity was determined using a mix of self-reported medical history, con-
comitant medications, health care resource use, and laboratory parameters. Principal component analysis (PCA) based on Somers’ 
D statistic was applied to identify patterns of comorbidities.
Results. PCA identified 6 patterns among the 1073 POPPY PLWH (85.2% male; median age [interquartile range {IQR}], 52 
[47–59] years): cardiovascular diseases (CVDs), sexually transmitted diseases (STDs), mental health problems, cancers, metabolic 
disorders, chest/other infections. The CVDs pattern was positively associated with cancer (r = .32), metabolic disorder (r = .38), 
mental health (r = .16), and chest/other infection (r = .17) patterns (all P < .001). The mental health pattern was correlated with all 
the other patterns (in particular cancers: r = .20; chest/other infections: r = .27; both P < .001). In the 598 AGEhIV PLWH (87.6% 
male; median age [IQR], 53 [48–59] years), 6 patterns were identified: CVDs, chest/liver, HIV/AIDS events, mental health/neurolog-
ical problems, STDs, and general health. The general health pattern was correlated with all the other patterns (in particular CVDs: 
r = .14; chest/liver: r = .15; HIV/AIDS events: r = .31; all P < .001), except STDs (r = –.02; P = .64).
Conclusions. Comorbidities in PLWH tend to occur in nonrandom patterns, reflecting known pathological mechanisms and 
shared risk factors, but also suggesting potential previously unknown mechanisms. Their identification may assist in adequately 
addressing the pathophysiology of increasingly prevalent multimorbidity in PLWH.
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Widespread access to combination antiretroviral therapy 
(cART) has led to a marked improvement in the survival and 
life expectancy of people living with HIV (PLWH) [1, 2] and 
to an increase of proportions of PLWH over the age of 50 years 
in most settings [3]. As a result of this demographic shift, a 
high prevalence of multimorbidity, defined as the occurrence 
of multiple comorbidities within the same individual, has been 
reported among PLWH with implications for health outcomes 
and functional status [4–6]. However, knowledge about how 
individual comorbidities distribute or co-occur in the same 
individual among PLWH remains limited.
Managing individuals with multiple acute or chronic comor-
bidities is typically more challenging than managing individuals 
with a single condition [7, 8]. Current HIV guidelines [9, 10] 
recommend close monitoring of cardiovascular, metabolic, 
liver, kidney, and bone health and regular assessment of drug–
drug interactions. Investigating common patterns, associations, 
interactions, and possible synergies between comorbidities 
could support further development of targeted interventions 
and guidelines for prevention and management of PLWH expe-
riencing multiple comorbidities.
Assessment of patterns of comorbidities is complicated by 
“coincidental comorbidity”—the co-occurrence of 2 or more 
comorbidities by chance [11]. The identification of comor-
bidities that are more likely to occur together than would be 
expected by chance can reveal disease–disease interactions or 
indicate shared etiologies between comorbidities. It is therefore 
important to separate coincident (random) comorbidity from 
nonrandom comorbidity. Modern statistical methods allow the 
exploration of the underlying structure in the distribution of 
comorbidities, giving an overall picture of the broad pattern of 
how comorbidities cluster in a particular population.
A recent report from the HIV and Aging Working Group 
called for the collection of better observational data to identify 
common clusters (patterns) of comorbidities among PLWH and 
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their impact on treatment and disease outcomes [12]. Although 
some studies have attempted to do so in the general popula-
tion using statistical approaches without any a priori hypothesis 
[13], to the best of our knowledge, only 2 studies have focused 
on PLWH [14, 15]. These studies considered up to 15 comorbid-
ities but were unable to include the broad spectrum of comor-
bidities and medical conditions that are commonly reported by 
PLWH, and therefore the patterns among a more comprehen-
sive set of comorbidities observed in PLWH remain unclear.
The aims of this study were (1) to explore (noncoincidental) 
associations between comorbidities in 2 independent cohorts 
of PLWH, (2) to investigate common patterns of comorbidi-
ties using a data-driven statistical approach, and (3) to evaluate 
associations between the patterns identified.
METHODS
This study is based on data from 2 European cohorts of PLWH: 
the POPPY study in the UK/Ireland and the AGEhIV study in 
the Netherlands. Both studies aimed to investigate the effects of 




The POPPY study recruited 2 cohorts of PLWH: an “older” 
group of PLWH aged ≥50 years and a younger group of PLWH 
aged 18–50  years, as described previously [16]. Inclusion cri-
teria were documented presence of HIV infection, white or 
black-African ethnicity, likely route of HIV acquisition via sex-
ual exposure, and ability to comprehend the study information 
leaflet. The younger group of PLWH was frequency-matched 
on gender, ethnicity, sexual orientation, and location (in or out 
of London) to the older PLWH. In addition, the study recruited 
a group of HIV-negative individuals aged ≥50 years, who was 
not included in the present analysis. Participants were recruited 
from HIV outpatient clinics between April 2013 and January 
2016. The study was approved by the UK National Research 
Ethics Service (NRES; Fulham, London, UK, number 12/
LO/1409). All participants provided written informed consent.
Data Collection
At study entry, a full clinical history of participants was captured 
detailing comorbidities and clinical conditions but also medi-
cations and health care resources used over the previous year. 
This information was self-reported by the study participants 
through a structured interview with trained staff who, where 
possible, also reviewed hospital notes to validate the presence 
of comorbidities. Participants were asked whether they ever 
experienced any of the comorbidities or medical conditions on 
a detailed list (Supplementary Table 1). For each organ system/
pathophysiological group, participants were also asked to report 
a history of any other relevant comorbidity not included in the 
study protocol. Answers to these free-text questions were exam-
ined to update the existing list of comorbidities or to include 
additional ones. Reasons for any health care utilization over 
the previous year (including general practitioner visit, hospital 
visit, use of ambulance or hospital transport, psychiatrist/psy-
chologist visit, nurse visit, specialist visit, hospital procedure, 
and health care provider) and information regarding any other 
(nonantiretroviral) medication received in the previous year 
were also scrutinized, and the presence of each comorbidity was 
updated accordingly. Congenital diseases and conditions with 
a prevalence <1.5% in the study population were subsequently 
excluded, yielding a total of 65 individual comorbidities from 19 
organ system/pathogenic groups (Table 1).
The AGEhIV Study
Study Participants
The AGEhIV study recruited PLWH aged ≥45 years from the 
HIV outpatient clinic of the Academic Medical Centre in 
Amsterdam, the Netherlands [17], between October 2010 and 
September 2012. Inclusion criteria were age ≥45  years and 
laboratory-confirmed presence of HIV infection. Although a 
control group of HIV-negative individuals was also enrolled 
in the study, these individuals were not included in the present 
analysis. The study protocol was approved by the local ethics 
review committee (ClinicalTrial.gov identifier NCT01466582). 
All participants provided written informed consent.
Data Collection
Participants underwent standardized screening for several 
comorbidities, including a questionnaire concerning personal 
medical history, use of medications (both prescribed and over the 
counter), and participation in population screening programs. 
Information concerning blood pressure, anthropometrics, vas-
cular elasticity, respiratory function (via spirometry test), cogni-
tive function, frailty, and bone densitometry (using DXA scan) 
was also obtained, in addition to blood and urine samples for 
extensive laboratory testing and historical HIV characteristics 
(from the Dutch HIV Monitoring Foundation registry).
Information collected was used to derive the presence/absence 
of 42 of the 65 comorbidities in Table 1, as well as a further 4 
(esophageal candidiasis, hyperparathyroidism, liver problems, 
and thrombocytopenia). Whenever possible, patient-reported 
comorbidities were validated using hospital records. The list of 
comorbidities obtained and the source of information for each 
comorbidity are reported in Supplementary Table 2.
Statistical Analysis
Comparison of participants’ characteristics between the older 
POPPY PLWH and AGEhIV PLWH was performed using the 
chi-square or Wilcoxon rank-sum test, as appropriate. Pairwise 
associations between comorbidities were assessed using the 
Somers’ D statistic for binary variables, as proposed by Ng 
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measures of agreement in detecting nonrandom comorbid-
ity [19]. Briefly, Somers’ D measures the degree of association 
between 2 comorbidities other than that given by chance alone 
(the product of the prevalence of the individual comorbidities). 
Somers’ D ranges from –1 when there is perfect disagreement 
between the 2 comorbidities (ie, all individuals have either 1 or 
the other comorbidity) to 1 when there is perfect agreement (ie, 
all individuals either have both comorbidities or neither comor-
bidity), with 0 indicating that agreement equals that given by 
chance alone. The significance of the Somers’ D statistic was 
evaluated using permutation tests, with P <  .001 indicative of 
significant nonrandom association (reflecting the high number 
of pair-wise associations tested, ie, 2080).
Principal component analysis (PCA) was applied to the matrix 
containing the pairwise associations (as measured by Somers’ 
D) between the comorbidities. PCA is a data reduction method 
that transforms the original set of variables into a smaller set of 
principal components (PCs), which are linear combinations of 














AIDS events Tuberculosis 83 (7.7) ✓ Cardiovascular 
diseases
Myocardial infarction 41 (3.8) ✓
Cytomegalovirus 28 (2.6)  Angina pectoris 34 (3.2) ✓
Pneumocystis pneumonia 94 (8.8) ✓ Peripheral vascular disease 19 (1.7) ✓
Kaposi’s sarcoma 70 (6.5) ✓ Hypertension 229 (21.3) ✓
Other AIDS events 124 (11.6) ✓ Transient ischemic attack 31 (2.9) ✓
Infections Varicella zoster virus 155 (14.4) ✓ Coronary artery bypass 
grafting 
24 (2.2)
Fungal infection 54 (5.0) Heart failure 25 (2.3) ✓
Endocrine diseases Type 2 diabetes 62 (5.8) ✓ Bones and joint 
disorders
Joint inflammation/arthritis 224 (20.9) ✓
Lipodystrophy/lipoatrophy 24 (2.2) ✓ Joint replacement 24 (2.2)
Dyslipidemia 293 (27.3) ✓ Osteopenia/osteoporosis 69 (6.4) ✓
Hypothyroidism 22 (2.1) Joint/back pain 118 (11.0)
Mental health 
problems
Depression 367 (34.2) ✓ Osteoporotic fracture 136 (12.7) ✓
Anxiety 67 (6.2) Skin disorders Eczema/dermatitis 109 (10.2)
Panic attacks 20 (1.9) Psoriasis 47 (4.4)
Sleeping problems 71 (6.6) ✓ Sexually transmitted 
diseases
Chlamydia 245 (22.8) ✓
Nervous system 
problems
Dizziness/vertigo 116 (10.8) ✓ Gonorrhea 457 (42.6) ✓
Loss of consciousness 31 (2.9) ✓ Human papilloma virus 99 (9.2)
Epilepsy 45 (4.2) ✓ Herpes simplex virus 122 (11.4)
Encephalitis 16 (1.5) ✓ Lymphogranuloma 
venereum 
46 (4.3)
Peripheral neuropathy 43 (4.0) ✓ Syphilis 326 (30.4) ✓
Migraine/headache 33 (3.1) Gastro-intestinal 
disorders
Hernia 27 (2.5)
Respiratory diseases Asthma/bronchitis/chronic 
obstructive pulmonary 
disease
264 (24.6) ✓ Gastro-esophageal reflux 
disease 
70 (6.5)
Pneumonia 44 (4.1) ✓ Irritable bowel syndrome 30 (2.8)
Chest infection 114 (10.6) Genitourinary 
disorders
Urinary incontinence 62 (5.8) ✓
Hay fever/allergy 77 (7.2) ✓ Urinary tract infections 31 (2.9)
Hepatitis Hepatitis A 44 (4.1) Erectile dysfunction 75 (7.0) ✓
Hepatitis B 147 (13.7) ✓ Nonspecific urethritis 58 (5.4)
Hepatitis C 75 (7.0) ✓ Prostate dysfunction 31 (2.9)
Renal problem Renal problem 28 (2.6) ✓ Kidney stones 28 (2.6)
Cancer Skin cancer 67 (6.2) ✓ Ear dysfunction Ear dysfunction 40 (3.7)
Hematological cancer 22 (2.1) ✓ Eye problem Eye problem 81 (7.5) ✓
Solid organ cancer 75 (7.0) ✓ Vitamin D deficiency Vitamin D deficiency 19 (1.8) ✓
Anemia Anemia 28 (2.6) ✓
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the original variables. These PCs are determined so that they 
retain as much of the variability in the data set as possible, with 
the first component retaining the greatest amount of the varia-
tion present and the other components progressively retaining 
a decreasing amount of variation [20]. PCs can be interpreted as 
patterns of comorbidities, ie, groups of comorbidities frequently 
associated with each other. A comorbidity was regarded to be 
associated with a pattern if its correlation with the pattern was 
>.40. We adopted an oblimin rotation to allow PCs (patterns) to 
be associated within each other, thereby allowing the possibility 
of multiple patterns being present in the same individual. The 
number of PCs to be extracted was determined using the scree 
plot and the very simple structure criterion [21].
For each participant and each pattern, a severity score 
for that pattern was obtained using data on the presence/
absence of comorbidities and coefficients returned by the PCA. 
Correlations between patterns’ severity scores were evaluated 
using Spearman’s rank correlation coefficient (r). All the anal-
yses were performed separately in all POPPY PLWH, in older 
POPPY PLWH only, and in AGEhIV PLWH using the statistical 
software R, version 3.3.3.
RESULTS
Characteristics of the POPPY and AGEhIV Study Participants
The POPPY study recruited 699 older and 374 younger PLWH; 
598 PLWH were recruited into the AGEhIV Cohort Study. 
Sociodemographic and HIV-related characteristics are summa-
rized in Table 2. POPPY participants were predominantly male 
(85.2%), of white ethnicity (84.1%), and men who have sex with 
men (MSM; 76.0%). The median (interquartile range [IQR]) 
CD4+ T-cell count was 624 (475–811) cells/μL, and 89.9% had a 
suppressed viral load (<50 copies/mL).
Similarly, the majority of PLWH recruited in the AGEhIV 
study were male (87.6%), of Dutch origin (85.8%), and MSM 
(70.4%). When compared with the older POPPY PLWH, they 
were younger (P  <  .001) and had a lower body mass index 
(BMI; P < .001); however, there were no significant differences 
in terms of gender (P = .91), ethnicity (P = .61), or sexual ori-
entation (P = .09).
Individual Comorbidities
In POPPY PLWH, the prevalence of comorbidities ranged from 
1.6% (encephalitis) to 42.6% (gonorrhea) (Table  1), with also 
depression (34.2%), syphilis (30.4%), and dyslipidemia (27.3%) 
among the most prevalent comorbidities. In total, 97.2% of all 
POPPY PLWH and 98.6% of older POPPY PLWH reported ≥1 
comorbidity with a median (IQR) of 5 (3–7) and 6 (3–8) comor-
bidities per individual, respectively. Of the comorbidities con-
sidered in AGEhIV PLWH, hypertension (43.1%), osteopenia/
osteoporosis (42.6%), lipodystrophy/lipoatrophy (32.1%), and 
candidiasis (31.9%) were the most common (Supplementary 
Table  2). Overall, 98.7% had ≥1 comorbidity, with a median 
(IQR) of 5 (3–7) comorbidities per individual.
Nonrandom Associations Between Comorbidities
Significant nonrandom associations, based on the Somers’ D 
statistic, among POPPY PLWH are depicted in Figure  1 (all 
pairwise Somers’ D are reported in the Supplementary Data). 
Nonrandom associations within several cardiovascular dis-
eases (CVDs) were significant (top-right part of Figure 1); these 











 Male 914 (85.2) 612 (87.5) 302 (80.8) 524 (87.6)
 Female 159 (14.8) 87 (12.5) 72 (19.2) 74 (12.4)
Age, median (IQR), y 52 (47–59) 57 (53–62) 43 (37–47) 53 (48–59)
Ethnicity, No. (%)a
 Black-African 171 (15.9) 96 (13.7) 75 (19.8) 74 (12.4)
 White 902 (84.1) 603 (86.3) 299 (80.2) 513 (85.8)
 Other/unknown 0 (0.0) 0 (0.0) 0 (0.0)  11 (1.8)
Sexual orientation, No. (%)
 MSM/homosexual 816 (76.0) 548 (78.4) 268 (71.7) 369 (70.4)
 Heterosexual 257 (24.0) 151 (21.6) 106 (28.3) 177 (29.6)
BMI, median (IQR), kg/m2 25.5 (23.2–28.2) 25.7 (23.4–28.5) 25.2 (23.0–27.8) 24.3 (22.4–26.7)
Duration of HIV, median (IQR), y 13.2 (7.8–20.5) 15.8 (9.8–22.4) 9.7 (5.5–15.2) 12.0 (6.6–17.0)
CD4+ T-cell count, median (IQR), cells/mm3 624 (476–811) 610 (468–792) 661 (500–847) 565 (433–740)
Nadir CD4+ count, median (IQR), cells/mm3 202 (101–304) 180 (85–273) 253 (152–376) 170 (70–260)
On ART, No. (%) 1046 (97.5) 690 (98.7) 356 (95.2) 573 (95.8)
HIV RNA <50 copies/mL, No. (%) 965 (89.9) 644 (91.8) 323 (86.4) 545 (91.6)
aFor the AGEhIV participants, white refers to Dutch origin, black-African to African origin. 
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included hypertension, angina, heart failure, type 2 diabetes, 
lipodystrophy/lipoatrophy, dyslipidemia, transient ischemic 
attack (TIA), coronary artery bypass graft (CABG), myocardial 
infarction (MI), and renal problems. Other strong nonrandom 
associations were identified within mental health problems 
(depression, anxiety, and panic attacks), with depression also 
being associated with sleeping problems and irritable bowel 
syndrome (IBS), cancers (hematological cancer with both 
solid organ and skin cancer), and sexually transmitted diseases 
(STDs; in particular gonorrhea, chlamydia, lymphogranuloma 
venereum [LGV], syphilis, and hepatitis C virus).
Most of these nonrandom associations were maintained 
when the analysis was restricted to older POPPY PLWH 
(Figure 2A). In addition, a strong nonrandom positive associ-
ation was found between panic attacks and asthma/bronchitis/
chronic obstructive pulmonary disease (COPD), and a signifi-
cantly lower than expected co-occurrence of hypertension and 
LGV. A few of these significant nonrandom associations were 
also found in the AGEhIV PLWH (Figure 2B), namely the asso-
ciations between MI, angina and hypertension, those of dyslipi-
demia with TIA, MI and type 2 diabetes, and those between 
gonorrhea and chlamydia and between angina and heart failure.
Patterns of Comorbidities
The PCA in POPPY PLWH yielded 6 components explain-
ing 24.4% of the total variation in the original 65 comorbidi-
ties. Correlations between comorbidities and each pattern are 
reported in the Supplementary Data, with Table 3 reporting only 
comorbidities with a correlation >0.4 with each pattern. The 
first PC accounted for 6.2% of the variance and encompassed 
CVDs such as angina, CABG, MI, heart failure, hypertension, 
peripheral vascular disease (PVD), and renal problems. The 
second PC, with strong correlations with STDs (gonorrhea, 
chlamydia, LGV, syphilis, and hepatitis C), accounted for 5.0% 
of the variability. The third PC strongly correlated with mental 
health problems (depression, anxiety, and panic attacks). The 
fourth and fifth PCs included cancers (hematological, skin, and 
solid organ cancer) and metabolic disorders (dyslipidemia, lipo-
dystrophy/lipoatrophy, and hypertension), respectively. Finally, 
the sixth PC had the strongest correlation with chest problems 
(pneumonia, asthma/bronchitis/COPD, and chest infection), 
cytomegalovirus, and dizziness/vertigo.
In the older POPPY PLWH, the PCA returned 6 components 
explaining 24.8% of the total variability (Table 3; Supplementary 
Data). Several components were similar to those found among 
all POPPY PLWH: CVDs (first PC), STDs (second PC), can-
cers (fourth PC), and metabolic disorders (fifth PC). Similar to 
the “mental health” pattern in all POPPY PLWH, the third PC 
included mental health problems but with the addition of asthma/
bronchitis/COPD and dizziness/vertigo. Finally, the sixth PC 
correlated with hypothyroidism (0.46) and other AIDS events.
Some of the 6 patterns returned by the PCA in the AGEhIV 
PLWH, explaining 34.2% of the total variance, resembled those 
identified in the older POPPY PLWH. The first PC correlated 
with CVDs (dyslipidemia, hypertension, PVD, angina pectoris, 
and MI). The second PC included chest (asthma/bronchitis/
COPD) and liver problems (with hepatitis B). The third and 
fourth PCs were related to HIV/AIDS events and mental health/
neurological problems, respectively. The fifth included STDs 
(gonorrhea, chlamydia, and syphilis), and the sixth encom-
passed disorders associated with general health such as anemia, 
vitamin D deficiency, hyperparathyroidism, and heart failure.
IBS Depression Anxiety Hypothyroidism Eye problem































Figure 1. Significant nonrandom associations between comorbidities (as indicated by a significant Somers’ D at the 0.1% significance level) in all POPPY PLWH (n = 1073). 
The thickness of the line is directly proportional to the absolute value of the Somers’ D. Abbreviations: CABG, coronary artery bypass graft; CMV, cytomegalovirus; GERD, 
gastro-esophageal reflux disease; IBS, irritable bowel syndrome; LGV, lymphogranuloma venereum; MI, myocardial infarction; PLWH, people living with HIV; PVD, peripheral 
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Correlations Between Patterns
Correlations between patterns’ severity scores are reported in 
Table 4. In all POPPY PLWH, positive correlations of severity 
scores in the CVDs pattern were strongest with scores in the 
cancer (r = .32) and metabolic patterns (r = .38) and moderate 
with those in the mental health (r = .16) and chest/other infec-
tion (r = .17) patterns (all P < .001). A significant negative cor-
relation was also found between the CVDs and STDs patterns 
(r = –.10; P = .001), suggesting that PLWH with a higher burden 
of CVDs tend to have a lower number of STDs and vice versa. 
Generally, the severity of the mental health pattern was posi-
tively correlated with the severity of all other patterns, with the 
strongest evidence for cancers (r = .20; P < .001) and chest and 
other infections (r = .27; P < .001). Chest/other infections was 
also positively associated with cancers and metabolic patterns 
(r = .27 and r = .25, respectively; both P < .001).
In the older POPPY PLWH, higher CVDs severity scores 
were correlated with higher mental health/asthma (r = .22), can-
cer (r = .26), and metabolic (r = .34) scores (all P < .001). Mental 
health/asthma scores also correlated with all the remaining 
patterns, with correlations ranging between 0.11 (with STDs) 
and 0.25 (with other). Among AGEhIV PLWH, association of 
CVDs was strongest with HIV/AIDS events (r = .18; P < .001) 
and general health problems (r = .14; P < .001) but weak with 
other patterns. A higher severity of the general health pattern 
was correlated with higher severity in all the other patterns 
(CVDs; chest/liver: r = .15; P < .001; HIV/AIDS events: r = .31; 
P < .001; mental health/neurological problems: r = .08; P = .05) 
but not with STDs (r = –.02; P = .64).
DISCUSSION
This study explored associations between a wide range of comor-
bidities and identified common patterns occurring in 2 inde-
pendent cohorts of PLWH. Our findings suggest that, in PLWH, 
comorbidities do not co-occur at random and, in general, are 
likely to cluster in specific patterns, some of which are consistent 
across different cohorts. In particular, we found that patterns of 
CVDs, metabolic disorders, STDs, and mental health problems 
are present in treated PLWH from both the UK/Ireland and the 






























































Figure 2. Significant nonrandom associations between comorbidities (significant Somers’ D at the 0.1% significance level) in all older POPPY PLWH (A) and AGEhIV PLWH 
(B). The thickness of the line is directly proportional to the absolute value of the Somers’ D. Abbreviations: CABG, coronary artery bypass graft; CMV, cytomegalovirus; COPD, 
chronic obstructive pulmonary disease; IBS, irritable bowel syndrome; LGV, lymphogranuloma venereum; MI, myocardial infarction; PLWH, people living with HIV; PVD, 
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patterns of comorbidities identified through purely statistical 
approaches [14, 15] by considering a wider range of comorbidi-
ties and validating the results in 2 independent cohorts.
Nonrandom associations between CVDs such as angina, 
hypertension, MI, CABG, and heart failure (which formed 1 
of the patterns identified) reflect previously known patholog-
ical mechanisms and were also previously reported in HIV-
positive veterans [14] and in the general population [22–24]. 
Similarly, patterns of metabolic disorders are often reported 
in conjunction with CVDs in both PLWH [15] and the gen-
eral population [22, 23]. On the other hand, contrary to other 
studies that used a similar data-driven approach in PLWH 
[14, 15] and in the general population [22–24], we found fre-
quent co-occurrence of STDs, likely due to exposure to some 
shared risk factors (ie, risk-taking sexual behaviors) that are 
highly prevalent among populations of PLWH [25]. Moreover, 
in 1 of the 2 cohorts analyzed, we found links between several 
opportunistic infections (ie, candidiasis, pneumocystis pneu-
monia, and other AIDS-defining events). These links likely 
reflect past immunosuppression and were mainly present in 
long-term survivors, as also indicated by the association of 
the pattern’s severity score with age and time since HIV diag-
nosis (data not shown).
Although associations between mental health problems like 
depression, anxiety, and panic attacks can reflect true underly-
ing psychological distress and co-occurrence patterns have been 
reported in other studies [23, 24], they may also highlight a 
monitoring bias. Individuals reporting 1 of the problems tend to 
be more likely to also report the others. Moreover, in our study, 
mental health disorders were associated not only with each other, 
but also with neurological problems, especially in older PLWH. 
These results were also reported by Kirchberger et al. [26] and 
are consistent with the growing evidence about the bidirectional 
link between mental health and neurological disorders [27].
Interestingly, there was some overlap between patterns, as 
suggested by significant correlations between patterns’ sever-
ity scores. In particular, mental health problems appeared to 
be associated with almost all other patterns, including those 
of CVDs, STDs, and metabolic disorders. Although these 
findings are in line with reports of the strong link between 
physical and mental health [28, 29], the nature of these asso-
ciations is likely to be bidirectional. Poor physical health can 
lead to an increased risk of developing mental health prob-
lems, but, at the same time, individuals with several mental 
health disorders are often more likely to experience physical 
health conditions [30].
Table 3. PC Extracted by the PCA in All POPPY PLWH (A, n = 1073), Older POPPY PLWH Only (B, n = 699), and AGEhIV PLWH (C, n = 598) Groups
PC (% of Variance Explained) Meaning Comorbidities With Correlation >0.4 (Correlation With the PC)
A, All POPPY PLWH (n = 1073)
1 (6.2) CVDs Angina (0.66), CABG (0.66), MI (0.64), heart failure (0.59), hypertension (0.54), PVD (0.53), 
renal problem (0.42)
2 (4.9) STDs Gonorrhea (0.77), syphilis (0.67), LGV (0.66), chlamydia (0.64), hepatitis C (0.40)
3 (3.9) Mental health Depression (0.79), anxiety (0.58), panic attacks (0.50)
4 (3.5) Cancers Hematological cancer (0.75), skin cancer (0.64), solid organ cancer (0.49)
5 (3.1) Metabolic Dyslipidemia (0.71), lipodystrophy/lipoatrophy (0.57), hypertension (0.44)
6 (2.8) Chest and other infections CMV (0.49), pneumonia (0.49), dizziness/vertigo (0.44), asthma/bronchitis/COPD (0.42), 
chest infection (0.41)
B, Older POPPY PLWH (n = 699)
1 (5.7) CVDs Angina (0.67), heart failure (0.65), PVD (0.62), CABG (0.58), MI (0.57), hypertension (0.54), 
renal problems (0.44)
2 (5.0) STDs Gonorrhea (0.74), LGV (0.72), syphilis (0.69), chlamydia (0.63), hepatitis C (0.46)
3 (4.1) Mental health and asthma Depression (0.79), anxiety (0.58), panic attacks (0.50), asthma/bronchitis/COPD (0.45), 
dizziness/vertigo (0.40)
4 (3.7) Cancers Hematological cancer (0.78), skin cancer (0.64), solid organ cancer (0.54)
5 (3.3) Metabolic Dyslipidemia (0.71), lipodystrophy/lipoatrophy (0.43)
6 (3.0) Other Hypothyroidism (0.46), other AIDS events (0.46)
C, AGEhIV PLWH (n = 598)
1 (9.7) CVDs Dyslipidemia (0.73), Hypertension (0.64), PVD (0.60), angina pectoris (0.54), MI (0.51)
2 (6.2) Chest/liver Asthma/bronchitis/COPD (0.59), liver problems (0.55), hepatitis B (0.47), dizziness/vertigo (0.43)
3 (4.9) HIV/AIDS events Peripheral neuropathy (0.63), candidiasis (0.62), lipodystrophy (0.53), other AIDS event (0.48)
4 (4.9) Mental health & neurological 
problems
Eye problem (0.64), depression (0.63), urinary incontinence (0.50), loss of consciousness 
(0.48), sleeping problems (0.42), dizziness/vertigo (0.40)
5 (4.4) STDs Chlamydia (0.70), gonorrhea (0.67), syphilis (0.62)
6 (4.3) General health Heart failure (0.88), hyperparathyroidism (0.54), vitamin D deficiency (0.48), anemia (0.45)
For each principal component, comorbidities with a high correlation (>0.4) are reported.
Abbreviations: CABG, coronary artery bypass graft; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; LGV, lymphogranuloma venereum; 
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There are some limitations to our study that need to be con-
sidered. First, not all of the comorbidities considered required 
a medical diagnosis, and some consisted more of symptoms or 
treatments rather than actual diseases. Although no uniform 
list of comorbidities and medical conditions exists to define 
multimorbidity, the list of comorbidities considered here aimed 
to capture the broad spectrum of conditions affecting PLWH. 
Nevertheless, the use of a more standardized list of conditions 
and criteria for the ascertainment of the presence of conditions 
(eg, ICD codes) could have provided a more uniform set of con-
ditions and more replicable results. Second, the self-reported 
nature of data collection may have led to under- or over-re-
porting of some comorbidities. Although the 2 cohort studies 
(POPPY and AGEhIV) were conducted following similar pro-
tocols, not all comorbidities were assessed by both studies and 
differences across studies exist in how the presence/absence of 
some comorbidities was defined, which may have resulted in 
the differences in the patterns identified. Moreover, both the 
POPPY and AGEhIV cohorts were designed to be representa-
tive of the population of PLWH seen in care in the respective 
countries, where the majority of PLWH are white MSM; there-
fore, results could be less generalizable to cohorts of PLWH that 
include larger proportions of women, people of black-African 
ethnicity, or to cohorts in different HIV epidemic settings.
Our findings could be useful for both research and clinical 
purposes. With an increasingly aging population of PLWH [3] 
and the consequent increase in the prevalence of multimor-
bidity and its associated health care costs [31], a better under-
standing of how comorbidities cluster together would enable us 
to develop targeted interventions and appropriate guidelines 
addressing the needs of PLWH with multiple comorbidities. 
Further studies may help to elucidate the possible pathophysi-
ological pathways linking conditions with demonstrated co-oc-
currence prevalences higher than those expected by chance 
alone and their impact on health and treatment outcomes.
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